<DOC>
	<DOC>NCT01641926</DOC>
	<brief_summary>This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been treated with interferon.</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Must be able to adhere to dose and visit schedules ≥ 40 kg Hepatitis B surface antigen (HBsAg) positive for at least 6 months AntiHBs negative Female participants of childbearing potential must agree to use an acceptable method of contraception from at least 2 weeks prior to Day 1 and continue until at least 1 month after last dose of study drug Inclusion Criteria for HBeAg(+) participants: HBeAg(+) AntiHBe() Inclusion Criteria for HBeAg() participants: HBeAg() AntiHBe(+) Coinfection with the human immunodeficiency virus (HIV) or hepatitis C or hepatitis D virus Prior treatment with interferon for hepatitis B Use of nucleoside/nucleotide analogues within 6 months of the screening visit or at any time during the study Use of any investigational drug within 30 days of the screening visit Prior treatment with herbal remedies with known hepatotoxicity. All herbal remedies used for hepatitis B treatment must be discontinued before Day 1 Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy Diabetic and/or hypertensive with clinically significant ocular examination findings History of stroke or transient ischemic attack Immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], celiac disease, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, sarcoidosis, severe psoriasis requiring oral or injected treatment, or symptomatic thyroid disorder) Chronic pulmonary disease (e.g., chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis) Current or history of any clinically significant cardiac abnormalities/dysfunction Any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial Myelodysplastic syndromes Organ transplants (including hematopoietic stem cell transplants) other than cornea and hair Pregnant or nursing, or intending to become pregnant during the trial period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>